-
Posted by
Two Blokes May 5 -
Filed in
Stock
-
3 views
Liquidia Corporation's legal victory clears the path for Yutrepia's FDA approval and market entry, targeting PAH and PH-ILD, with final approval expected by May 24, 2025. Yutrepia's competitive advantages include a patient-friendly inhaler, lower cost structure, and strong clinical profile, positioning it to capture market share from United Therapeutics' Tyvaso DPI. Liquidia is financially prepared for Yutrepia's launch, boasting $176.5 million in cash and milestone financing, ensuring a smooth commercialization without diluting shareholders.
